PBA
Paradigm Biocapital Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $67.4M | Buy |
2,343,553
+397,385
| +20% | +$11.4M | 2.88% | 11 |
|
|
2025
Q1 | $65.3M | Buy |
1,946,168
+35,407
| +2% | +$1.19M | 2.99% | 9 |
|
|
2024
Q4 | $97.7M | Sell |
1,910,761
-605,925
| -24% | -$31M | 3.4% | 10 |
|
|
2024
Q3 | $129M | Buy |
2,516,686
+3,384
| +0.1% | +$173K | 4.35% | 5 |
|
|
2024
Q2 | $113M | Sell |
2,513,302
-611,447
| -20% | -$27.4M | 4.31% | 8 |
|
|
2024
Q1 | $146M | Buy |
3,124,749
+811,830
| +35% | +$38M | 5.15% | 5 |
|
|
2023
Q4 | $82.3M | Buy |
2,312,919
+134,182
| +6% | +$4.77M | 3.85% | 12 |
|
|
2023
Q3 | $64.8M | Buy |
2,178,737
+783,735
| +56% | +$23.3M | 4.4% | 10 |
|
|
2023
Q2 | $25.1M | Buy |
1,395,002
+261,220
| +23% | +$4.71M | 1.94% | 18 |
|
|
2023
Q1 | $18.2M | Buy |
1,133,782
+243,677
| +27% | +$3.91M | 1.73% | 21 |
|
|
2022
Q4 | $16.3M | Buy |
890,105
+370,849
| +71% | +$6.79M | 1.91% | 20 |
|
|
2022
Q3 | $10.2M | Buy |
+519,256
| New | +$10.2M | 1.36% | 22 |
|